Publication
Extended-Duration Betrixaban Reduces the Risk of Stroke Versus Standard-Dose Enoxaparin Among Hospitalized Medically Ill PatientsClinical Perspective
An APEX Trial Substudy (Acute Medically Ill Venous Thromboembolism Prevention With Extended Duration Betrixaban)
C. Michael Gibson, Gerald Chi, Rim Halaby, Serge Korjian, Yazan Daaboul, Purva Jain, Douglas Arbetter, Samuel Z. Goldhaber, Russel Hull, Adrian F. Hernandez, Alex Gold, Olga Bandman, Robert A. Harrington, Alexander T. Cohen
Circulation, November 2016, Wolters Kluwer Health
DOI: 10.1161/circulationaha.116.025427